PARIS (Reuters) – Valneva now expects a positive recommendation from the European Medecines Agency (EMA) in April for its VLA2001 COVID-19 candidate vaccine, the French vaccine maker said on Friday, compared to an earlier target for the end of March.
“Following such conditional approval, the company would expect to start delivering planned doses of VLA2001 to European countries in the second quarter of 2022,” said Valneva.
In February, Valneva had said it was hoping for such a recommendation by the end of this month.
(Reporting by Benoit Van Overstraeten; Editing by Sudip Kar-Gupta)
